Six1 mediates resistance to paclitaxel in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 441, Issue 3, 2013, Pages 538-543

  Li, Zhaoming ^a   Tian, Tian ^a   Hu, Xiaopeng ^b   Zhang, Xudong ^a   Nan, Feifei ^a   Chang, Yu ^a   Lv, Feng ^c   Zhang, Mingzhi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Apoptosis; Breast cancer; Paclitaxel resistance; Six1

Indexed keywords

PACLITAXEL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SIX1;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

APOPTOSIS; BREAST CANCER; PACLITAXEL RESISTANCE; SIX1;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MCF-7 CELLS; PACLITAXEL; RNA, SMALL INTERFERING;

EID: 84888299815     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.131     Document Type: Article

References (30)

1. Porter P.L. Global trends in breast cancer incidence and mortality. Salud Publica Mex. 2009, 51(Suppl. 2):s141-s146.
2. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
3. McGrogan B.T., Gilmartin B., Carney D.N., McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta 2008, 1785:96-132.
4. Christensen K.L., Patrick A.N., McCoy E.L., Ford H.L. The six family of homeobox genes in development and cancer. Adv. Cancer Res. 2008, 101:93-126.
5. Anderson A.M., Weasner B.M., Weasner B.P., Kumar J.P. Dual transcriptional activities of SIX proteins define their roles in normal and ectopic eye development. Development 2012, 139:991-1000.
6. Heanue T.A., Reshef R., Davis R.J., Mardon G., Oliver G., Tomarev S., Lassar A.B., Tabin C.J. Synergistic regulation of vertebrate muscle development by Dach2, Eya2, and Six1, homologs of genes required for Drosophila eye formation. Genes Dev. 1999, 13:3231-3243.
7. Xu P.X., Zheng W., Huang L., Maire P., Laclef C., Silvius D. Six1 is required for the early organogenesis of mammalian kidney. Development 2003, 130:3085-3094.
8. Kumar J.P. The sine oculis homeobox (SIX) family of transcription factors as regulators of development and disease. Cell. Mol. Life Sci. 2009, 66:565-583.
9. Coletta R.D., McCoy E.L., Burns V., Kawakami K., McManaman J.L., Wysolmerski J.J., Ford H.L. Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis. BMC Dev. Biol. 2010, 10:4.
10. Wang C.A., Jedlicka P., Patrick A.N., Micalizzi D.S., Lemmer K.C., Deitsch E., Casás-Selves M., Harrell J.C., Ford H.L. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J. Clin. Invest. 2012, 122:1895-1906.
11. McCoy E.L., Iwanaga R., Jedlicka P., Abbey N.S., Chodosh L.A., Heichman K.A., Welm A.L., Ford H.L. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:2663-2677.
12. Reichenberger K.J., Coletta R.D., Schulte A.P., Varella-Garcia M., Ford H.L. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res. 2005, 65:2668-2675.
13. Coletta R.D., Christensen K.L., Micalizzi D.S., Jedlicka P., Varella-Garcia M., Ford H.L. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res. 2008, 68:2204-2213.
14. Coletta R.D., Christensen K., Reichenberger K.J., Lamb J., Micomonaco D., Huang L., Wolf D.M., Müller-Tidow C., Golub T.R., Kawakami K., Ford H.L. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc. Natl. Acad. Sci. USA 2004, 101:6478-6483.
15. Iwanaga R., Wang C.A., Micalizzi D.S., Harrell J.C., Jedlicka P., Sartorius C.A., Kabos P., Farabaugh S.M., Bradford A.P., Ford H.L. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012, 14:R100.
16. Micalizzi D.S., Christensen K.L., Jedlicka P., Coletta R.D., Barón A.E., Harrell J.C., Horwitz K.B., Billheimer D., Heichman K.A., Welm A.L., Schiemann W.P., Ford H.L. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J. Clin. Invest. 2009, 119:2678-2690.
17. Farabaugh S.M., Micalizzi D.S., Jedlicka P., Zhao R., Ford H.L. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 2012, 31:552-562.
18. Smith A.L., Iwanaga R., Drasin D.J., Micalizzi D.S., Vartuli R.L., Tan A.C., Ford H.L. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012, 31:5162-5171. 10.1038/onc.2012.11.
19. Behbakht K., Qamar L., Aldridge C.S., Coletta R.D., Davidson S.A., Thorburn A., Ford H.L. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 2007, 67:3036-3042.
20. Menke C., Goncharov T., Qamar L., Korch C., Ford H.L., Behbakht K., Thorburn A. TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One 2011, 6:e14527.
21. Li Z., Tian T., Lv F., Chang Y., Wang X., Zhang L., Li X., Li L., Ma W., Wu J., Zhang M. Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression. PLoS One 2013, 8:e59203.
22. Bauer J.A., Chakravarthy A.B., Rosenbluth J.M., Mi D., Seeley E.H., De Matos Granja-Ingram N., Olivares M.G., Kelley M.C., Mayer I.A., Meszoely I.M., Means-Powell J.A., Johnson K.N., Tsai C.J., Ayers G.D., Sanders M.E., Schneider R.J., Formenti S.C., Caprioli R.M., Pietenpol J.A. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res. 2010, 16:681-690.
23. Luo X., Li Z., Li X., Wang G., Liu W., Dong S., Cai S., Tao D., Yan Q., Wang J., Leng Y., Gong J., Hu J. HSav1 interacts with HAX1 and attenuates its anti-apoptotic effects in MCF-7 breast cancer cells. Int. J. Mol. Med. 2011, 28:349-355.
24. Murray S., Briasoulis E., Linardou H., Bafaloukos D., Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat. Rev. 2012, 38:890-903.
25. Curigliano G. New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. Cancer Treat. Rev. 2012, 38:303-310.
26. Lai D., Ho K.C., Hao Y., Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011, 71:2728-2738.
27. Lv K., Liu L., Wang L., Yu J., Liu X., Cheng Y., Dong M., Teng R., Wu L., Fu P., Deng W., Hu W., Teng L. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One 2012, 7:e40008.
28. Sun X., Li D., Yang Y., Ren Y., Li J., Wang Z., Dong B., Liu M., Zhou J. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity. J. Pathol. 2012, 226:666-673.
29. Inoue S., Salah-Eldin A.E., Omoteyama K. Apoptosis and anticancer drug resistance. Hum. Cell 2001, 14:211-221.
30. Galletti E., Magnani M., Renzulli M.L., Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007, 2:920-942.